FOX Translator
No data currently available.
No data currently available.
In the wide and varied family of the thousands and thousands of funds out there, the exchange-traded fund is one of the more consumer-friendly ones.
Unlike mutual funds, exchange-traded funds, or ETFs, behave more like stocks. You can buy
into an ETF at any time, and sell it whenever you feel like it. And like a stock, an ETF's value can rise and fall--depending
on what the ETF is invested in.What do ETFs invest in? Well, they're typically linked to an index like the Dow Jones Industrial
Average or the S&P 500. So, if you had an ETF that trades the same companies that make up the Dow or the S&P, it will
rise and fall in value pretty much the same amount as the Dow or S&P.
You can also buy ETFs that invest in other
types of products, like bonds, currencies, gold or other commodities. The ETF market has grown considerably in the past few
years, so there is no shortage of ETFs to invest in.
Home / Markets / Industries / Health Care
Wednesday, July 02, 2008
MediciNova to Host Analyst/Investor Meeting in New York City
Comtex
SAN DIEGO, Jul 2, 2008 (PrimeNewswire via COMTEX) ----MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced it will host an analyst/investor meeting in New York City on Wednesday, July 9, 2008. Presentations will begin at 8:00 A.M., Eastern time.
MediciNova management will provide a corporate update and overview of MediciNova's two lead product development programs: MN-166, an orally administered compound for multiple sclerosis, and MN-221, an intravenously administered compound for status asthmaticus. In addition to presentations by MediciNova management, speakers will include Dr. Andrew R. Pachner, Professor, Department of Neurology and Neurosciences at UMDNJ -- New Jersey Medical School, and Dr. Robert A. Silverman, Associate Clinical Professor of Emergency Medicine at Albert Einstein College of Medicine.
Interested parties may access a live audio webcast of the event through MediciNova's website at http://www.medicinova.com. A conference call will also be available for interested parties. To participate in this call, dial 866-272-9941 (domestic), 617-213-8895 (international), passcode: 34185117, shortly before 8:00 A.M., Eastern time. The audio webcast will be available on MediciNova's website (www.medicinova.com) for approximately 60 days following the event.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, an acute, severe asthma attack, and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit www.medicinova.com.
The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: MediciNova, Inc.
MediciNova, Inc. Shintaro Asako, Chief Financial Officer (858) 373-1500 info@medicinova.com Rx Communications Group, LLC Rhonda Chiger (917) 322-2569 rchiger@rxir.com
(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
